1. Home
  2. Analysis
  3. Neosar
  4. Perjeta

Neosar and Perjeta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neosar (cyclophosphamide) and Perjeta (pertuzumab). Common drug interactions include alopecia among females.

The phase IV clinical study analyzes what interactions people have when they take Neosar and Perjeta. It is created by eHealthMe based on reports of 80 people who take the same drugs from the FDA, and is updated regularly.

What is Neosar?

Neosar has active ingredients of cyclophosphamide. eHealthMe is studying from 12,352 Neosar users. Check the latest studies of Neosar.

What is Perjeta?

Perjeta has active ingredients of pertuzumab. eHealthMe is studying from 13,388 Perjeta users. Check the latest studies of Perjeta.

On Aug, 13, 2026

80 people who take Neosar and Perjeta together, and have interactions are studied.

Neosar and Perjeta drug interactions.

What are the common drug interactions of Neosar and Perjeta, by gender? *:

female:

  1. Alopecia (absence of hair from areas of the body)
  2. Hair colour changes
  3. Hair disorder
  4. Psychological trauma
  5. Anxiety
  6. Emotional distress
  7. Pain
  8. Depression
  9. Alopecia areata (patchy baldness that typically begins with rapid hair loss)

male:

n/a

What are the common drug interactions of Neosar and Perjeta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Alopecia (absence of hair from areas of the body)
  2. Hair colour changes
  3. Hair disorder

40-49:

  1. Alopecia (absence of hair from areas of the body)
  2. Hair colour changes
  3. Hair disorder
  4. Psychological trauma
  5. Anxiety
  6. Emotional distress
  7. Pain
  8. Alopecia areata (patchy baldness that typically begins with rapid hair loss)

50-59:

  1. Psychological trauma
  2. Emotional distress
  3. Anxiety
  4. Pain
  5. Depression
  6. Alopecia (absence of hair from areas of the body)
  7. Hair colour changes
  8. Hair disorder

60+:

  1. Alopecia (absence of hair from areas of the body)
  2. Hair colour changes
  3. Hair disorder
  4. Anxiety
  5. Psychological trauma
  6. Depression
  7. Emotional distress

What are the existing conditions these people have? *

  1. Breast Cancer Female: 53 people, 66.25%
  2. Breast Cancer Metastatic: 11 people, 13.75%
  3. Breast Cancer: 9 people, 11.25%

* Approximation only. Some reports may have incomplete information.

Do you take Neosar and Perjeta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Neosar and Perjeta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neosar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Perjeta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neosar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Perjeta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on cyclophosphamide and pertuzumab (the active ingredients of Neosar and Perjeta, respectively), and Neosar and Perjeta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.